Issue navigation
Volume 18, Issue 3, March 2024
Editorials
Adalimumab: A ‘Maillon Faible’ in the Treatment of Ulcerative Colitis?
Journal of Crohn's and Colitis, Volume 18, Issue 3, March 2024, Pages 337–338, https://doi.org/10.1093/ecco-jcc/jjad167
Refining the Concept of Microscopic Colitis: HLA Signatures Discriminating Collagenous and Lymphocytic Colitis
Journal of Crohn's and Colitis, Volume 18, Issue 3, March 2024, Pages 339–340, https://doi.org/10.1093/ecco-jcc/jjad211
Original Articles
Prospective Observational Evaluation of the Time-Dependency of Adalimumab Immunogenicity and Drug Concentration in Ulcerative Colitis Patients: the POETIC II Study
Journal of Crohn's and Colitis, Volume 18, Issue 3, March 2024, Pages 341–348, https://doi.org/10.1093/ecco-jcc/jjad156
Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis Subtypes
Journal of Crohn's and Colitis, Volume 18, Issue 3, March 2024, Pages 349–359, https://doi.org/10.1093/ecco-jcc/jjad165
Prevalence of Hepatobiliary Manifestations in Inflammatory Bowel Disease: A GRADE Assessed Systematic Review and Meta-Analysis of more than 1.7 Million Patients
Journal of Crohn's and Colitis, Volume 18, Issue 3, March 2024, Pages 360–374, https://doi.org/10.1093/ecco-jcc/jjad157
Temporary Faecal Diversion for Refractory Perianal and/or Distal Colonic Crohn’s Disease in the Biologic Era: An Updated Systematic Review with Meta-analysis
Journal of Crohn's and Colitis, Volume 18, Issue 3, March 2024, Pages 375–391, https://doi.org/10.1093/ecco-jcc/jjad159
Plasminogen Activator Inhibitor 1 Is a Novel Faecal Biomarker for Monitoring Disease Activity and Therapeutic Response in Inflammatory Bowel Diseases
Journal of Crohn's and Colitis, Volume 18, Issue 3, March 2024, Pages 392–405, https://doi.org/10.1093/ecco-jcc/jjad160
Submucosal Injection of the RNA Oligonucleotide GUT-1 in Active Ulcerative Colitis Patients: A Randomized, Double-Blind, Placebo-Controlled Phase 2a Induction Trial
Journal of Crohn's and Colitis, Volume 18, Issue 3, March 2024, Pages 406–415, https://doi.org/10.1093/ecco-jcc/jjad162
Maintenance Risankizumab Sustains Induction Response in Patients with Crohn’s Disease in a Randomized Phase 3 Trial
Journal of Crohn's and Colitis, Volume 18, Issue 3, March 2024, Pages 416–423, https://doi.org/10.1093/ecco-jcc/jjad168
Tofacitinib for Patients with Anti-TNF Refractory Ulcerative Proctitis: A Multicentre Cohort Study from the GETAID
Journal of Crohn's and Colitis, Volume 18, Issue 3, March 2024, Pages 424–430, https://doi.org/10.1093/ecco-jcc/jjad169
Baseline Expression of Immune Gene Modules in Blood is Associated With Primary Response to Anti-TNF Therapy in Crohn’s Disease Patients
Journal of Crohn's and Colitis, Volume 18, Issue 3, March 2024, Pages 431–445, https://doi.org/10.1093/ecco-jcc/jjad166
NLRP3 Inhibition Leads to Impaired Mucosal Fibroblast Function in Patients with Inflammatory Bowel Diseases
Journal of Crohn's and Colitis, Volume 18, Issue 3, March 2024, Pages 446–461, https://doi.org/10.1093/ecco-jcc/jjad164
Review Articles
Matrix metalloproteinases in intestinal fibrosis
Journal of Crohn's and Colitis, Volume 18, Issue 3, March 2024, Pages 462–478, https://doi.org/10.1093/ecco-jcc/jjad178
Patient-reported Outcome Measures in Ileoanal Pouch Surgery: a Systematic Review
Journal of Crohn's and Colitis, Volume 18, Issue 3, March 2024, Pages 479–487, https://doi.org/10.1093/ecco-jcc/jjad163
Short Report
Mitigating the Risk of Tofacitinib-induced Adverse Events in the Elderly Population with Ulcerative Colitis
Journal of Crohn's and Colitis, Volume 18, Issue 3, March 2024, Pages 488–491, https://doi.org/10.1093/ecco-jcc/jjad158
Letter to the Editor
6-Mercaptopurine in ulcerative colitis: the potential of upfront dosing with allopurinol
Journal of Crohn's and Colitis, Volume 18, Issue 3, March 2024, Page 492, https://doi.org/10.1093/ecco-jcc/jjad150
